The life sciences sector is at a crossroads as the FDA updates quality management standards. AI is now expected, and the FDA’s January 2025 draft guidance outlines its evaluation and implementation. Successful adoption depends on three key questions.
Safe and Sane: Understanding the FDA’s Risk-Based Approach to AI
Related Posts
Why Guidewire Programs Fail: The Missing Layer of Assurance Enterprises Must Know
Insurers today have gone beyond the role of merely safeguarding and compensating for losses. They have moved into…
Top 10 API Testing Tools in Software Testing Industry
Content 1. API Testing Outlook in 2023 and Beyond 2. Benefits of API Testing in Agile 3. Key…
Massivit 3000 Large-Format 3D Printer
Company has received two additional strategic purchase orders from Bombardier, Canadian Aerospace Company and Navistar.